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Abstract: BACKGROUND Several preclinical and epidemiologic studies have indicated tumour-promoting
effects of thyroid hormones (THs). However, very limited knowledge exists on the prognostic impact of
thyroid function in metastatic cancer. METHODS We compiled a discovery cohort of 1692 patients with
newly diagnosed brain metastases (BMs) of solid cancers treated at the Medical University of Vienna and
an independent validation cohort of 191 patients with newly diagnosed BMs treated at the University
Hospital Zurich. RESULTS Hypothyroidism before diagnosis of cancer was evident in 133 of 1692 (7.9%)
patients of the discovery, and in 18 of 191 (9.4%) patients of the validation cohort. In the discovery
cohort, hypothyroidism was statistically significantly associated with favourable survival prognosis from
diagnosis of cancer (31 vs. 21 months; p = 0.0026) and with survival prognosis from diagnosis of BMs
(12 vs. 7 months; p = 0.0079). In multivariate analysis including the diagnosis-specific graded prognostic
assessment score, primary tumour type and sex, hypothyroidism was an independent factor associated
with survival after diagnosis of BMs (hazard ratio: 0.76; 95% confidence interval [CI]: (0.63; 0.91; p =
0.0034). In the validation cohort, the association of hypothyroidism and favourable survival prognosis
from diagnosis of cancer (55 vs. 11 months; p = 0.00058), as well as from diagnosis of BMs (40 vs.
10 months; p = 0.0036) was confirmed. CONCLUSION Pre-existing hypothyroidism was strongly and
independently associated with prognosis in patients with newly diagnosed BMs, supporting the evidence
from preclinical data that THs may indeed have a tumour-promoting effect. Further investigation of the
underlying pathobiological mechanism and potential therapeutic implications are required.
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Abstract Background: Several preclinical and epidemiologic studies have indicated tumour-
promoting effects of thyroid hormones (THs). However, very limited knowledge exists on the
prognostic impact of thyroid function in metastatic cancer.
Methods: We compiled a discovery cohort of 1692 patients with newly diagnosed brain metas-
tases (BMs) of solid cancers treated at the Medical University of Vienna and an independent
validation cohort of 191 patients with newly diagnosed BMs treated at the University Hospital
Zurich.
Results: Hypothyroidism before diagnosis of cancer was evident in 133 of 1692 (7.9%) patients
of the discovery, and in 18 of 191 (9.4%) patients of the validation cohort. In the discovery
cohort, hypothyroidism was statistically significantly associated with favourable survival
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prognosis from diagnosis of cancer (31 vs. 21 months; pZ 0.0026) and with survival prognosis
from diagnosis of BMs (12 vs. 7 months; p Z 0.0079). In multivariate analysis including the
diagnosis-specific graded prognostic assessment score, primary tumour type and sex, hypothy-
roidism was an independent factor associated with survival after diagnosis of BMs (hazard ra-
tio: 0.76; 95% confidence interval [CI]: (0.63; 0.91; p Z 0.0034). In the validation cohort, the
association of hypothyroidism and favourable survival prognosis from diagnosis of cancer (55
vs. 11 months; pZ 0.00058), as well as from diagnosis of BMs (40 vs. 10 months; pZ 0.0036)
was confirmed.
Conclusion: Pre-existing hypothyroidism was strongly and independently associated with
prognosis in patients with newly diagnosed BMs, supporting the evidence from preclinical
data that THs may indeed have a tumour-promoting effect. Further investigation of the un-
derlying pathobiological mechanism and potential therapeutic implications are required.
ª 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Cancer is a leading cause of death worldwide, even
though the development of molecularly targeted thera-
pies has improved patient’s survival times [1]. Brain
metastases (BMs) occur most frequently in patients with
metastatic lung cancer, breast cancer or melanoma and
represent a particularly devastating complication, as
curative treatments are lacking so far [2]. Furthermore,
the neurological symptoms of BMs severely impact the
quality of life of affected patients, leaving this cohort in
particular clinical need for new therapeutic approaches.
Biological factors driving metastatic spread are of high
clinical interest for the development of new targeted
therapeutic approaches [3].
Thyroid hormones (THs) have been reported to
impact cancer growth. Several preclinical studies suggest
that TH suppression by pharmacological inhibition or
thyroid resection reduces cancer growth rates [4e6].
Epidemiological studies further supported this preclini-
cal observation of TH-induced tumour growth as a
higher risk of ovarian, pancreatic, prostate and lung
cancer has been observed in patients with hyperthy-
roidism and subsequent TH excess [7]. In line, patients
with hypothyroidism were shown to be older at the
diagnosis of breast cancer, suggesting that the metabolic
hypothyroid state actually might slow down tumour
development and progression [8,9]. However, despite
promising evidence from these preclinical and epidemi-
ological investigations, comprehensive analyses of the
prognostic impact of thyroid function in patients with
frequent cancer types, for example, lung cancer and
breast cancer, have not been undertaken. Therefore, we
investigated the prognostic impact of thyroid function in
a large, well defined cohort of patients suffering from
metastatic cancer and BMs, as well as an independent
validation cohort to investigate the clinical correlation
of thyroid function with survival.
2. Material and methods
2.1. Patients
Patients suffering from metastatic cancer and treated for
newly diagnosed BM at the Medical University of
Vienna between 1990 and 2017 were identified from the
Vienna Brain Metastasis Registry (‘discovery cohort’).
Further, an independent cohort of patients treated for
newly diagnosed BMs at the University Zurich between
2004 and 2017 was identified (‘validation cohort’). The
discovery and the validation cohort were treated by in-
dependent multidisciplinary teams in accordance with
good clinical practice guidelines.
History of hypothyroidism was defined as treatment
with TH substitution and mentioning of ‘hypothyroid-
ism’ in the diagnosis section of the patient. Clinical
symptoms of hypothyroidism were not reported. Pa-
tients with documented hyperthyroidism in their past
medical history and/or treatment with thyreostatics were
included in the hyperthyroidism group.
A broader spectrum of clinical data was obtained in
the discovery cohort including thyroid-stimulating
hormone (TSH), as well as free triiodothyronine (fT3),
T3, free thyroxine (fT4) and T4 levels. Lower limit of
normal, upper limit of normal (ULN) and normal
range (NR) were defined in accordance with the central
laboratory (Department of Laboratory Medicine,
Medical University of Vienna). NR for TSH was .44 to
3.77 mIU/ml, for fT3 2.15e4.12 pg/ml, for fT4
0.76e1.66 ng/dl, for T3 0.8e1.8 ng/ml and for T4
58e124 ng/ml. The diagnosis-specific graded prognostic
assessment (DS-GPA) score was calculated based on
clinical parameters including age, Karnofsky perfor-
mance score, number of BMs and status of the extra-
cranial disease [10].
This project was approved by the ethics committee of
the Medical University of Vienna (078/2004).
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2.2. Statistical analysis
Overall survival from diagnosis of cancer was defined
from diagnosis of cancer to death or last follow-up.
Time to BM development was defined as time from
diagnosis of cancer to diagnosis of BM. Overall survival
from diagnosis of BM was defined as the time from
radiological BM diagnosis to death or last follow-up.
Differences between groups were assessed using the chi
square test, the Kruskal-Wallis test, and the Mann-
Whitney U test as appropriate. The Kaplan-Meier
product limit method was used to estimate survival
times, and the log rank test was used to estimate survival
differences between groups. For multivariate survival
analyses, a Cox proportional hazards model was applied
to adjust for other pre-specified prognostic factors such
as DS-GPA, classified in class I-IV, primary tumour and
sex. Owing to the hypothesis generating design of the
present study no correction for multiple testing was
applied. A two-tailed p-value 0.05 was considered to
indicate statistical significance. Statistical analysis was
performed with Statistical Package for the Social Sci-
ences (SPSS) 23.0 software (SPSS Inc., Chicago, IL,




One thousand six hundred ninety-two patients (775
males, 45.8%; 917 females, 54.2%) with a median age at
diagnosis of cancer of 59 years (range: 24e89) and a
median time of 8 months (range: 0e25) until diagnosis
of BMs were included in the discovery cohort. Primary
tumours included lung cancer (1183/1692; 69.9%), breast
cancer (411/1692; 24.3%) and melanoma (98/1692;
5.8%). None of the included patients were treated with
immune checkpoint inhibitor therapy or vascular
endothelia growth factor receptor directed tyrosine ki-
nase inhibitors and in consequence none of the observed
thyroid dysfunction was caused by systemic treatment.
DS-GPA was available for all patients and 180 patients
(10.6%) belonged to class I, 578 patients (34.2%) to class
II, 632 patients (37.4%) to class III and 302 patients
(17.8%) to class IV. Median survival from BM diagnosis
in the entire cohort was 7 months (range: 0e196), and
only 102 patients (6%) were still alive at the last follow-
up. DS-GPA class showed an association with survival
from diagnosis of BM in univariate analysis (p < 0.001;
log rank test). Table 1 lists further characteristics of the
discovery cohort.
3.1.2. Validation cohort
One hundred ninety-one patients (113 males, 59.2%; 78
females, 40.8%) with a median age of 63 years (31e89)
at the diagnosis of cancer were included in the validation
cohort. Primary tumours were lung cancer in 172 pa-
tients (90.1%), breast cancer in 4 patients (2.1%), mela-
noma in 14 patients (7.3%), and a parotid tumour in 1
patient (0.5%). No patient was treated with immune
checkpoint inhibitors, and in consequence none of the
observed thyroid dysfunctions were caused by such
therapy. Table 2 lists further characteristics of the vali-
dation cohort.
3.2. Thyroid function in patients with BMs
3.2.1. Discovery cohort
One hundred thirty-three patients (7.9%) were diag-
nosed with hypothyroidism and 33 patients (2%) were
Table 1
Patient characteristics of the discovery cohort.
Characteristics n Z 1692 %
Age at diagnosis of BM, years Median 59
Range 24e89
Sex Male 775 45.8
Female 917 54.2
Cancer entity Lung cancer 1183 69.9
Breast cancer 411 24.3
Melanoma 98 5.8




DS-GPA score Class I 180 10.6
Class II 578 34.2
Class III 632 37.4
Class IV 302 17.8
History of thyroid dysregulation


















DS-GPA, diagnosis-specific graded prognostic assessment.
Table 2
Patient characteristics of the validation cohort.
Characteristics n Z 191 %
Age at diagnosis of BM, years Median 62.84
Sex Male 113 59.2
Female 78 40.8
Cancer entity Lung cancer 172 90.1
Breast cancer 4 2.1
Melanoma 14 7.3
Parotid tumour 1 0.5
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diagnosed with hyperthyroidism before the diagnosis of
cancer (Table 1). Twenty-six patients (1.5%) had hypo-
thyroidism due to thyroid surgery for a benign nodule,
13 patients (0.8%) due to autoimmune thyroiditis, and
83 patients (4.9%) for unknown reasons. TSH values
before the diagnosis of cancer were available in 357
patients (21.1%). Median TSH before diagnosis of can-
cer was higher in patients with history of hypothyroid-
ism compared with patients without history of
hypothyroidism (2.1 vs. 1.2 mIU/ml; p Z 0.008; Mann-
Whitney U test). TSH higher than the ULN before
cancer diagnosis was statistically more frequently
observed in patients with history of hypothyroidism
(14.6% vs. 4.1%; pZ 0.011; chi Square test). fT3 values
before the diagnosis of cancer were available for 125
patients (7.4%) and fT4 values for 234 patients (13.8%).
fT3 and fT4 values were not different between patients
with and without history of hypothyroidism (p > 0.05;
Mann-Whitney U test).
Female patients presented more frequently with a
history of hypothyroidism (12.0% vs. 3.1%; p < 0.001;
Chi Square test). In line, hypothyroidism was most
frequently observed among patients with breast cancer
(49/411; 11.9%) followed by lung cancer (78/1183; 6.5%)
and patients with melanoma (6/98; 6.1% p Z 0.001; chi
Square test; Table 3). Presence of the endothelia growth
factor receptor (EGFR) mutation had no impact on the
frequency of hypothyroidism in the patients with non-
esmall-cell lung cancer BMs. Three of 12 (25%) patients
with history of hypothyroidism presented with EGFR
mutation and 23 of 106 (21.7%) patients without history
of hypothyroidism presented with EGFR mutation
(p > 0.05; chi Square test).
3.2.2. Validation cohort
Eighteen patients (9.4%) were diagnosed with hypothy-
roidism and 2 patients (1.0%) with hyperthyroidism
before the diagnosis of cancer (Table 2). Breast cancer
patients presented more frequently with hypothyroidism
(1/4; 25.0%) than lung cancer (14/172; 8.1%), or mela-
noma (2/14; 14.3%) patients (p Z 0.009; chi Square
test). Frequency of hypothyroidism did not differ by sex
(p Z 0.182; chi Square test; Table 4).
3.3. Correlation of thyroid function with clinical course in
the discovery cohort
Time from diagnosis of primary tumour to BM diag-
nosis was longer in patients with a history of hypothy-
roidism (median 14 months, 95% confidence interval
[CI]: 10e23) than in patients without a history of hy-
pothyroidism (median 8 months, 95% CI: 7e9;
p Z 0.014; log rank test; Fig. 1A). No correlation with
time to BMs development was evident for history of
hyperthyroidism (8 vs. 14 months; p Z 0.908; log rank
test).
Extracranial disease burden did not differ between
patients with (88/136; 64.7%) versus patients without
(924/1571; 58.8%; p Z 0.180; chi Square test) hypothy-
roidism. In line, median number of involved extracranial
organs did not correlate with history of hypothyroidism
(p Z 0.777; Mann-Whitney U test). Further, no differ-
ence in the number of BMs at diagnosis (pZ 0.583; chi
square test) or in the DS-GPA class (p Z 0.849; chi
square test) in accordance with history of hypothyroid-
ism was observed (Table 3).
Table 3










N % N %
Age at diagnosis of BM, years Median 60 58 0.173
Range 33e88 24e89
Sex Male 24 18.0 751 48.2 <0.001
Female 109 82.0 808 51.8
Cancer entity Lung cancer 78 58.6 1105 70.9 0.002
Breast cancer 49 36.8 363 23.3
Melanoma 6 4.5 92 5.9
Extracranial metastases at BM diagnosis Yes 85 63.9 912 58.5 0.223
No 48 36.1 647 41.5
Karnofsky performance status Median 80 80 0.694
Range 30e100 10e100
Number of BMs Median 1 2 0.528
Range 1e20 1e22
DS-GPA score Class I 25 18.8 277 17.8 0.761
Class II 50 37.6 582 37.3
Class III 41 30.8 537 34.4
Class IV 17 12.8 163 10.5
DS-GPA diagnosis-specific graded prognostic assessment.
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TSH values at diagnosis of BM were available in 892
patients (52.7%), fT3 values in 149 patients (8.8%), and
fT4 values in 585 patients (34.6%). Median TSH and
median fT3 did not differ between patients with and
without history of hypothyroidism. fT4 values at diag-
nosis of BM were higher in patients with a history of
hypothyroidism (1.5 versus 1.2 ng/dl; p < 0.001; Mann-
Whitney U test).
TSH values after radiotherapy were available in 936
patients (55.3%) patients. Twelve (1.3%) of these pa-
tients developed hypothyroidism after radiotherapy for
BMs and needed TH replacement therapy. Six of 441
(1.4%) patients developed hypothyroidism after stereo-
tactic radiosurgery, 6 of 179 (3.3%) after whole-brain
radiotherapy, whereas none of the patients treated with
neurosurgery without further radiation, chemotherapy
or best supportive care developed hypothyroidism
(p > 0.05; chi square test). None of the investigated
patients presented with newly onset hyperthyroidism
during cancer treatment.
3.4. Correlation of thyroid function with survival
3.4.1. Discovery cohort
History of hypothyroidism before diagnosis of cancer
was associated with longer survival from diagnosis of
cancer (median 31 months, 95% CI: (25e42) vs. median
21 months, 95% CI: (19e22); pZ 0.0026; log rank test;
Fig. 1B): and with longer survival from diagnosis of
BMs (median 12 months, 95% CI: (9e14) vs. median 7
months, 95% CI: (7e8); p Z 0.0079; log rank test;
Fig. 1C). Cause of hypothyroidism and survival from
diagnosis of cancer showed no association (p Z 0.310;
log rank test), although numerically patients with his-
tory of autoimmune thyroiditis had longer survival time
(median: 54 months) than patients with unknown cause
(median: 30 months) or thyroid surgery (median: 32
months).
As history of hypothyroidism correlated with sex and
primary tumour type, multivariate analysis including
history of hypothyroidism, sex, primary tumour type, as
well as the established prognostic score DS-GPA was
performed to analyse whether history of hypothyroid-
ism is statistically independently associated with sur-
vival prognosis. In multivariate analysis including DS-
GPA (hazard ratio [HR]: 1.48; 95% CI (1.38e1.58);
p < 0.0001), primary tumour type (breast cancer) (HR:
1.20; 95% CI: (0.83e1.74); p Z 0.3342), primary
tumour type (melanoma) (HR: 2.85; 95% CI:
(1.58e5.17); p Z 0.0005), and sex (HR: 0.900; 95% CI:
(0.801e1.010); p Z 0.074), history of hypothyroidism
before diagnosis of cancer was independently associated
with survival after diagnosis of BM (HR: 0.76; 95% CI:
(0.63e0.91); p Z 0.0034; Cox regression model). The
association of hypothyroidism with survival after diag-
nosis of BM was observed to be homogeneous across
the subgroups formed by the predefined factors of
Fig. 1. Association of hypothyroidism and survival times in the
discovery cohort: Time from diagnosis of cancer to diagnosis of
BMs (A), as well as survival from diagnosis of cancer (B) and from
diagnosis of BMs (C) was longer in hypothyroid patients.
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interest, although less for patients in DS-GPA class I.
Nevertheless, all confidence intervals in the subgroups
of interest cover the regression coefficient (RC) estimate
in the full population indicating consistent results across
subgroups. In detail, history of hypothyroidism was
associated with survival prognosis in the subgroups of
male (RC: -0.28; 95% CI: 0.72 to 0.15), female (RC:
-0.20; 95% CI: 0.40 to 0.01), patients with lung cancer
(RC -0.27; 95% CI 0.51 to 0.04), patients with breast
cancer (RC: -0.12; 95% CI: 0.42 to 0.19), patients with
melanoma (RC: -0.74; 95% CI 1.65 to 0.18), as well as
patients with DS-GPA class I (RC: 0.22; 95% CI: 0.29
to 0.73), class II (RC: -0.36; 95% CI: 0.68 to 0.03),
class III (RC: -0.25; 95% CI: 0.55 to 0.05) and class IV
(RC: -0.40; 95% CI: 0.82 to 0.02]; Fig. 2).
3.5. Validation cohort
In line with the discovery cohort, patients with hypo-
thyroidism had longer overall survival from primary
tumour diagnosis (median: 55 months, 95% CI: 40-NA)
than patients without hypothyroidism (median: 11
months, 95% CI: 7e15; p Z 0.00058; log rank test;
Fig. 3A). Further, patients with hypothyroidism had
longer overall survival from diagnosis of BM (median:
40 months, 95% CI: 36-NA) than patients without hy-
pothyroidism (median: 10 months, 95% CI: 7e15;
p Z 0.0036; log rank test; Fig. 3B).
4. Discussion
The association of thyroid function and cancer pro-
gression has been addressed by several preclinical and
Table 4










N % N %
Age at diagnosis of BM, years Median 55.5 64 0.040
Range 33.76 31e89
Sex Male 8 44.4 105 60.7 0.182
Female 10 55.6 68 39.3
Cancer entity Lung cancer 14 77.8 158 91.3 0.009
Breast cancer 1 5.6 3 1.7
Melanoma 2 11.1 12 6.9
Parotid tumour 1 0.5 0 0
Fig. 2. Association of hypothyroidism across subgroups defined by multiple factors with survival time from diagnosis of brain metastases
in the discovery cohort. RC Z regression coefficient. Sample Size (SS) is given for each subgroup and further divided based on their
history of hypothyroidism.
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epidemiological studies, however, the present study
identifies a prognostic role of thyroid function in two
independent cohorts of patients with brain metastatic
cancer [5,7]. History of hypothyroidism was associated
with slowed disease progression as hypothyroid patients
presented with a longer survival from diagnosis of can-
cer, a longer time until development of BMs, as well as a
longer survival from diagnosis of BMs in the discovery
and independent validation cohort.
Previous epidemiological studies postulated that hy-
pothyroid breast cancer patients are older at diagnosis,
indicating that TH depletion might slow down cancer
development and progression [8]. However, other
epidemiological studies e.g. in patients with ovarian
cancer reported conflicting results suggesting that hy-
perthyroidism and overall history of hypothyroidism are
associated with worse 5-year survival [11]. A case report
of a patient suffering from metastatic nonesmall-cell
lung cancer surviving a myxoedema coma and
subsequent stabilization of cancer progression for more
than 5 years, was the basis for clinical attempts to
interfere with TH signalling in patients with cancer [12].
Chemical hypothyroidism was induced successfully
using the antithyroid thioamide, i.e. propylthiouracil,
followed by carboplatin chemotherapy or tamoxifen
therapy in patients with glioblastoma, however efficacy
data are not yet sufficiently available to evaluate clinical
activity [13,14]. The present investigation represents a
large investigation of thyroid function in patients with
metastatic cancer. Our data supports the clinical rele-
vance of TH signalling in cancer; however causal rela-
tion cannot be proven by the present data as prospective
clinical trials are needed to investigate an actual clinical
impact rather than mere association. Certainly, the
induced hypothyroid state has to be induced with
caution and patients should not experience related
symptoms. Indeed, the patients in the present cohort
were all substituted resulting in a normalization of TSH
values but slightly increased fT4 values. In consequence,
strategies actively inducing light, subclinical hypothy-
roidism or restricted TH replacement in patients with
hypothyroid cancer could be investigated.
We can only speculate on the mechanistical expla-
nations of the association of hypothyroidism with sur-
vival in patients with cancer. Insights from preclinical
animal models indicate that the tumour suppressing ef-
fect of hypothyroidism might be mediated via the avb3
integrin signalling pathway, as THs regulate the
expression of a large panel of genes relevant to cancer
cell proliferation, cancer cell survival and tumour-linked
angiogenesis [15,16]. avb3 integrin expression can be
more frequently observed on BMs tumour cells
compared with the matched primary tumour, support-
ing the theory that activation might be associated with
metastatic spread [17]. Indeed, preclinical inhibition of
integrin signalling using an av antibody resulted in
smaller and less invasive BMs growth [18,19]. Further
mechanistical research is needed to identify the causal
relations and potential treatment targets in the TH sig-
nalling cascade in cancer.
Patients with a history of hypothyroidism more
frequently had TSH values higher than the ULN.
However, all patients received treatment and therefore
the majority of TSH values, also in patients with history
of hypothyroidism, presented within the NR. The
standard thyroid substitution is a T4 formulation and as
a pro-hormone, T4 must be converted to T3 in the tissue
by iodothyronine deiodinases to acquire biological ac-
tivity [20]. Patients treated with levothyroxine (T4) were
shown to not achieve serum levels of T3 within the NR
owing to inadequate conversion, which results in a high
T4/T3 serum ratio [21]. In contrast to peripheral tissues,
the hypothalamus is less susceptible to an increased T4/
T3 ratio and in consequence the TSH is normalized
before adequate T3 availability can be achieved in the
peripheral tissues. Animal studies suggest that actually
Fig. 3. Association of hypothyroidism and survival in the valida-
tion cohort: Overall survival from diagnosis of cancer (A) and
from diagnosis of BMs (B).
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the combination of levothyroxine (T4) plus liothyronine
(T3) could normalize mitochondrial content and a-
glycerophosphate dehydrogenase activity e both
markers of T3-responsiveness in the liver and skeletal
muscle e and circulating cholesterol concentrations
better than levothyroxine (T4) treatment alone [22].
Therefore, the observed association of hypothyroidism
with survival despite the levothyroxine substitution and
a normalized TSH value, might be caused by and
inadequate T4/T3 ratio, preserving a hypothyroid status
in the tumour tissue. A more detailed examination of
TSH, fT3 and fT4 values, as well as an assessment of the
presence of autoimmune antibodies in a prospective
cohort would be of interest to further identify the un-
derlying cause of the association of survival and hypo-
thyroidism; however due to the retrospective design not
all parameters were available in the entire cohort.
Although the validation cohort could support the
investigated correlation of hypothyroidism and survival,
the available clinical data were limited compared with
the discovery cohort. Nevertheless, given the clear same
prognostic association in this independent cohort,
treated at a different center in a different country,
strongly supports the observed association of thyroid
function of survival prognosis in patients with BMs.
5. Conclusions
In conclusion, we report an association of thyroid
function and survival in a well characterized, large
cohort, as well as in an independent validation cohort of
patients with metastatic cancer. Our data supports the
theory that TH withdrawal might impede cancer growth
via the interference with pro-neoplastic molecular
pathways, although causal relation have to be addressed
in subsequent preclinical studies [5]. Investigation of the
underlying molecular mechanisms might allow the
identification of promising new treatment targets.
Further studies, specifically investigating the underlying
pathways are needed to draw potential therapeutic
conclusions and design trials investigating targeted
therapies.
Funding
The present study was supported by an unrestricted
research grant of Daiichi Sankyo (UE71101084).
Conflict of interest statement
A.S.B. has received research support from Daiichi
Sankyo (10000V), Roche (>10000V); has received
honoraria for lectures;has been a member of the
consultation or advisory board participation from
Roche Bristol-Meyers Squibb, Merck, Daiichi Sankyo
(all < 5000V), has received travel support from Roche,
Amgen and AbbVie. M.K. has received research sup-
port from Sanofi, AstraZeneca and Ipsen; served as a
speaker and received consulting fees from AstraZeneca,
Novartis, Novo Nordisk, Lilly, Merck, Böhringer,
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